NewCardio Information

NewCardio is a science and technology driven company with the mission of fully developing and commercializing a three dimensional (3D) approach to electrocardiography (ECG) in order to increase the diagnostic value of the most widely used cardiology test. Ultimately our vision is to add value to each and every ECG as it is currently utilized in practice today, as well as extending its use to include, but not be limited to, replacing more costly, and sometimes invasive and potentially harmful, diagnostic procedures. The company is developing and validating a novel, patent pending 3D ECG platform technology to dramatically improve the quality, timeliness and cost of the standard 12-lead ECG for diagnosing common acute and chronic heart disease and for evaluating cardiac safety of new drugs. NewCardio's 3-dimensional ECG approach allows faster, more accurate and less expensive assessment of cardiac status. And what is important in the development of the advanced science and technology underlying our approach is that the NewCardio platform technology relies on the standard 12-lead ECG signal as the input, requiring no change in how the 12-lead ECG is obtained.